Source-grounded facts extracted from TriSalus Life Sciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
TriSalus Life Sciences, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-14 meeting.
“The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers was approved by the stockholder vote: For Against Abstain Broker Non-Votes 32,625,082 1,206,105 176,369 7,721,120”
TriSalus Life Sciences, Inc. shareholders approved Advisory vote on frequency of future stockholder advisory votes on named executive officer compensation at the 2026-05-14 meeting.
“The proposal to approve, on an advisory basis, a three-year frequency with which the Company should conduct future stockholder advisory votes on named executive officer compensation was approved by the stockholder vote: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 12,656,430 736,931 20,348,386 265,809 7,721,120”
TriSalus Life Sciences, Inc. shareholders approved Ratification of appointment of Grant Thornton, LLP as independent registered accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-14 meeting.
“The appointment of Grant Thornton, LLP to serve as our independent registered accounting firm for the fiscal year ending December 31, 2026 was ratified by the stockholder vote: For Against Abstain 41,098,385 28,667 601,624”
TriSalus Life Sciences, Inc. shareholders approved Election of Directors at the 2026-05-14 meeting.
“The two nominees for Directors were elected to serve three-year terms to expire at the annual meeting of stockholders in 2029, as follows: Nominee For Withhold Broker Non-Votes Mary Szela 31,393,310 2,614,246 7,721,120 Gary Gordon 31,339,161 2,668,395 7,721,120”
TriSalus Life Sciences, Inc. reported the quarter ended March 31, 2026 results: revenue $8.9 million, net income $1.5 million, EPS $0.03.
“Revenue from the sale of the TriNav system, was $8.9 million for the three months ended March 31, 2026, a decrease of 2.9% compared to the same period in 2025.”
Dr. Richard Marshall was appointed as Chief Medical Officer at TriSalus Life Sciences, Inc..
“As previously announced on April 7, 2026, the Company appointed Dr. Richard Marshall to Chief Medical Officer of the Company, effective June 29, 2026.”
Jodi Devlin departed as Chief of Clinical Operations at TriSalus Life Sciences, Inc..
“On April 24, 2026, Jodi Devlin provided notice to TriSalus Life Sciences, Inc. (the “Company”) of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026.”
TriSalus Life Sciences, Inc. reported 2026 results: revenue $60 million to $62 million. Guidance reaffirmed.
“Reaffirms 2026 Revenue Guidance of $60-62 million”
TriSalus Life Sciences, Inc. reported the year ended December 31, 2025 results: revenue $45.2 million, net income $69.7 million, EPS $1.84.
“Revenue, all from sales of the TriNav system, was $45.2 million for the year ended December 31, 2025, an increase of 53% compared to the same period in 2024.”
TriSalus Life Sciences, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $13.2 million.
“Generated $13.2 million in net sales, a 60% increase year-over-year”
TriSalus Life Sciences, Inc. entered into Underwriting Agreement with Lake Street Capital Markets, LLC (effective 2026-02-19).
“On February 19, 2026, TriSalus Life Sciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC (“LSCM”), as representative of the underwriters named therein (the “Underwriters”), relating to the public offering (the “Offering”) of 9,756,100 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), at a price to the public of $4.10 per Share (the “Offering Price”).”
TriSalus Life Sciences, Inc.: Amended Certificate of Designations for Series A Convertible Preferred Stock to permit mandatory conversion upon closing of the exchange offer (effective 2025-07-24).
“on July 24, 2025, the Company filed the Preferred Stock Amendment with the Secretary of State of the State of Delaware. The Preferred Stock Amendment will permit the Company to require that all shares of Preferred Stock that are outstanding upon the closing of the Offer be converted into the number of shares of Common Stock equal to the quotient of (i) the sum of (a) the Liquidation Preference (as defined in the Certificate of Designations (defined below)) and (b) the Accrued Dividends (as defined in the Certificate of Designations) if not otherwise paid by the Company, that would have accrued through closing the Offer (the “Exchanged Value”), divided by the Conversion Price (as defined in the Certificate of Designations, as such term will be amended by the Preferred Stock Amendment.”
David Patience was appointed as Chief Financial Officer at TriSalus Life Sciences, Inc..
“On May 27, 2025, the Company entered into an offer letter with David Patience for the position of Chief Financial Officer.”
James Young resigned as Chief Financial Officer at TriSalus Life Sciences, Inc..
“Mr. Young resigned from the Company for personal reasons, effective May 30, 2025.”
George Kelly Martin resigned as Member of the Board, Audit Committee, and Compensation Committee at TriSalus Life Sciences, Inc..
“On April 20, 2025, George Kelly Martin informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of his decision to resign from his position as a member of the Board, the Audit Committee of the Board and the Compensation Committee of the Board, effective immediately.”
Liselotte Hyveled resigned as Member of the Board at TriSalus Life Sciences, Inc..
“On April 16, 2025, Liselotte Hyveled informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of her decision to resign from her position as a member of the Board, the Nominating and Corporate Governance Committee of the Board and the Science and Technology Committee of the Board, effective immediately.”
Sean Murphy departed as other at TriSalus Life Sciences, Inc..
“On February 19, 2025, Sean Murphy notified TriSalus Life Sciences, Inc. (the “Company”) of his intent to step down as an officer and employee of the Company effective February 28, 2025.”
TriSalus Life Sciences, Inc. incurred term loan of $10 million with OrbiMed Royalty & Credit Opportunities IV, LP maturing April 30, 2029.
“y ”) and TriSalus Operating Life Sciences, Inc., a Delaware corporation and wholly owned subsidiary of the Company (the “ Borrower ”) entered into a Credit Agreement (the “ Credit Agreement ”), by and between the Company, as parent, the Borrower, as borrower, OrbiMed Royalty & Credit Opportunities IV, LP, a Delaware limited partnership (the “ Initial Lender ”), as a lender, each other lender that may from time to time become a party thereto, and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the lenders.”
Gary Gordon was appointed as Director at TriSalus Life Sciences, Inc..
“On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.”
William Valle was appointed as Director at TriSalus Life Sciences, Inc..
“On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.”
Sean Murphy was appointed as Chief Manufacturing, Strategy and Business Development Officer at TriSalus Life Sciences, Inc..
“appointing Sean Murphy to Chief Manufacturing, Strategy and Business Development Officer”
James Young changed role as Chief Financial Officer at TriSalus Life Sciences, Inc..
“promoting James Young to Chief Financial Officer, Secretary, Treasurer and principal financial and accounting officer of the Company”
Steven Katz departed as Chief Medical Officer at TriSalus Life Sciences, Inc..
“Effective October 29, 2024, Steven Katz, M.D., the Company’s Chief Medical Officer, is no longer employed by the Company.”
Anil Singhal resigned as Director at TriSalus Life Sciences, Inc..
“On October 28, 2024, Anil Singhal, Ph.D., informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of his decision to resign from his position as a member of the Board, the Compensation Committee of the Board and the Science and Technology Committee of the Board, effective immediately.”
TriSalus Life Sciences, Inc. reported first quarter ended March 31, 2024 results: revenue $6.5 million, net income $13.2 million, EPS $0.60.
“TriSalus Reports Q1 2024 Financial Results and Business Update · Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 · Reported Gross Margin of 85% in 1Q24”
TriSalus Life Sciences, Inc. incurred credit facility of $25 million with OrbiMed Royalty & Credit Opportunities IV, LP at SOFR plus 8.50% maturing April 30, 2029.
“On April 30, 2024, the Borrower borrowed the Initial Commitment Amount, resulting in gross proceeds to the Borrower of $25 million.”
TriSalus Life Sciences, Inc. entered into Credit Agreement with OrbiMed Royalty & Credit Opportunities IV, LP valued at Up to $50 million senior secured credit facility, $25 million initial borrowing on April 30, 2024, $ (effective 2024-04-30).
“On April 30, 2024 (the “ Closing Date ”), TriSalus Life Sciences, Inc., a Delaware corporation (the “ Company ”) and TriSalus Operating Life Sciences, Inc., a Delaware corporation and wholly owned subsidiary of the Company (the “ Borrower ”) entered into a Credit Agreement (the “ Credit Agreement ”), by and between the Company, as parent, the Borrower, as borrower, OrbiMed Royalty & Credit Opportunities IV, LP, a Delaware limited partnership (the “ Initial Lender ”), as a lender, and each other lender that may from time to time become a party thereto (each, including the Initial Lender, and together with their affiliates, successors, transferees and assignees, the “ Lenders ”), and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the Lenders (in such capacity, the “ Administrative Agent ”).”
TriSalus Life Sciences, Inc. engaged Grant Thornton LLP as its auditor.
“On April 12, 2024, the Audit Committee approved the engagement of Grant Thornton LLP”
TriSalus Life Sciences, Inc. dismissed KPMG LLP as its auditor.
“(a) Dismissal of Independent Registered Public Accounting Firm On April 12, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of TriSalus Life Sciences, Inc. (the “Company”) approved the dismissal of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm. On April 12, 2024, KPMG was informed that they were dismissed. KPMG’s audit reports on the Company’s consolidated financial statements as of and for the years ended December 31, 2023 and 2022, did not contain any adverse opinion or a disclaimer”
TriSalus Life Sciences, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“On April 1, 2024, TriSalus Life Sciences, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the quarter and year ended December 31, 2023.”
TriSalus Life Sciences, Inc. reported fiscal year-ended December 31, 2023 results: revenue approximately $5.7 million for the fourth quarter of 2023.
“On March 11, 2024, TriSalus Life Sciences, Inc. (the “Company”) announced a preliminary unaudited financial update with respect to the Company’s fiscal year-ended December 31, 2023.”
TriSalus Life Sciences, Inc. reported preliminary financial results for the year ended December 31, 2023.
“TriSalus Life Sciences, Inc. (the “Company”) may use a slide presentation, in whole or in part, from time to time in presentation to investors, analysts and others that includes preliminary sales information for the year ended December 31, 2023, as well as a business and product update.”
TriSalus Life Sciences, Inc. reported the three and nine month periods ended September 30, 2023 results: revenue $5.2 million, net income $1.7 million and $27.0 million, respectively, for the third quarter and nine months ended September 30, 2023, EPS Basic and diluted loss per share for the three and nine months ended September 30, 2023, was $0.
“Financial Results and Provides Business Update Completed merger with MedTech Acquisition Corporation (MTAC) and started public trading August 11 th Reported 3Q23 revenues of $5.2 million in 3Q23, up 32% over prior year and nine-month year to date net revenues of $12.8 million, up 39% over prior year Favorable Phase 1 uveal melanoma PERIO-01 data demonstrating”
TriSalus Life Sciences, Inc. entered into Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville) valued at up to $30,000,000 (effective 2023-10-02).
“On October 2, 2023, TriSalus Life Sciences, Inc. (the “Company”) entered into a Standby Equity Purchase Agreement (the “Purchase Agreement”) with YA II PN, Ltd. (“Yorkville”).”
TriSalus Life Sciences, Inc.: MTAC ceased to be a shell company as a result of the Business Combination (effective 2023-08-10).
“MTAC ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the Closing”
TriSalus Life Sciences, Inc.: Approved and adopted a new Code of Business Conduct and Ethics (effective 2023-08-10).
“on August 10, 2023, the New TriSalus Board approved and adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors of the Company”
TriSalus Life Sciences, Inc.: Adopted Amended and Restated Bylaws (effective 2023-08-10).
“also adopted Amended and Restated Bylaws on August 10 , 2023 (the “Bylaws”), which replaced MTAC’s Amended and Restated Certificate of Incorporation and bylaws in effect as of such time”
TriSalus Life Sciences, Inc.: Filed Certificate of Incorporation with amendments proposed by Charter Proposal (effective 2023-08-10).
“On August 10, 2023, the Company filed the Certificate of Incorporation with the Delaware Secretary of State”
TriSalus Life Sciences, Inc. underwent a change of control (closed 2023-08-10).
“As a result of the consummation of the Business Combination, a change of control of MTAC has occurred, and the stockholders of MTAC as of immediately prior to the Closing held 9.7% of the outstanding shares of New TriSalus Common Stock immediately following the Closing.”
TriSalus Life Sciences, Inc. shareholders approved Director Nomination Proposal B at the 2023-08-08 meeting.
“7B. Director Nomination Proposal B : i. David J. Matlin For Withheld 7,135,005 19,016”
TriSalus Life Sciences, Inc. shareholders approved Director Nomination Proposal A at the 2023-08-08 meeting.
“7A. Director Nomination Proposal A : i. Anil Singhal For Withheld 7,135,005 19,016”
TriSalus Life Sciences, Inc. shareholders approved The Nasdaq Proposal at the 2023-08-08 meeting.
“6. The Nasdaq Proposal : For Against Abstain 7,135,005 19,016 0”
TriSalus Life Sciences, Inc. shareholders approved The ESPP Proposal at the 2023-08-08 meeting.
“5. The ESPP Proposal : For Against Abstain 7,135,000 19,021 0”
TriSalus Life Sciences, Inc. shareholders approved The Stock Plan Proposal at the 2023-08-08 meeting.
“4. The Stock Plan Proposal : For Against Abstain 7,135,000 19,021 0”
TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3E at the 2023-08-08 meeting.
“3E. Governance Proposal 3E : For Against Abstain 7,135,005 19,016 0”
TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3D at the 2023-08-08 meeting.
“3D. Governance Proposal 3D : For Against Abstain 7,135,005 19,016 0”
TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3C at the 2023-08-08 meeting.
“3C. Governance Proposal 3C : For Against Abstain 7,135,005 19,016 0”
TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3B at the 2023-08-08 meeting.
“3B. Governance Proposal 3B : For Against Abstain 7,135,005 19,016 0”
TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3A at the 2023-08-08 meeting.
“3A. Governance Proposal 3A : For Against Abstain 7,134,005 20,016 0”
TriSalus Life Sciences, Inc. shareholders approved The Charter Approval Proposal at the 2023-08-08 meeting.
“2. The Charter Approval Proposal : i. Class A Common Stock For Against Abstain 7,135,004 19,016 0 ii. Class B Common Stock For Against Abstain 1 0 0 iii. Total Common Stock For Against Abstain 7,135,005 19,016 0”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.